CRMD: CorMedix Inc Company Value to Net Income

Corporate emblem and logo of CorMedix Inc (CRMD)

Combating catheter-related infections through partnerships with nephrologists defines the development vector for CorMedix Inc. (CRMD). The price-to-earnings trend visualizes the market valuation of this process, where 5.80 shows the value of this parameter. The effective product launch under competent management is complemented by strict adherence to environmental standards for biohazardous waste disposal, which stabilizes the asset's investment attractiveness.

CorMedix Inc (CRMD) Price to Earnings Ratio: for the period 07/04/2022 - 11/15/2026

Comprehensive metric breakdowns and analytics for CorMedix Inc (CRMD)

- price and consensus price forecast:
Stock Price CorMedix Corp|CRMD - Consensus Target
- market capitalization information:
Market Value CorMedix Inc|CRMD - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share CorMedix|CRMD - Company Book Value|Capitalization to Book Value Ratio cormedix.com|CRMD - Company Total Assets
- debt and solvency information:
Aggregate Debt to Equity CorMedix Inc.|CRMD - Long-Term Debt to Capital|Current Liabilities to Capital CorMedix Inc.|CRMD - Company Aggregate Debts|Debt to Book Value CorMedix Therapeutics|CRMD - Company Long-Term Liabilities|Amount of Current Liabilities CorMedix|Interim Coverage Ratio cormedix.com
- earnings and market multiples details:
CRMD - Company Net Income|Expected Net Profit CorMedix Inc.|CRMD - Price to Earnings Ratio|Price to Future Earnings Ratio CorMedix Therapeutics|CRMD - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio CorMedix Inc|CRMD - Operating profit EBITDA|Net earnings per share for the last 12 months CorMedix|CRMD - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months cormedix.com|CRMD - Earnings per share growth in current year|Expected earnings per share trend next year CorMedix Inc.
- sales volume and revenue indicators:
CRMD - Company Revenue|Company Future Sales Volume CorMedix|CRMD - P/S Multiple|Market Cap to Future Revenue Ratio CorMedix Inc|CRMD - Sales Growth YoY (TTM)
Summary company analysis:CRMD CorMedix Corp
Manufactured products of CorMedix

CorMedix Inc. (CRMD) maintains a critical dependence on a single antibacterial drug, rendering the business's market value sensitive to the pace of its clinical adoption. While the relationship between the current price and net income, reflected in the company's historical average P/E, determines the investment payback period, ignoring the debt load when analyzing this metric may lead to an erroneous assessment of capital stability.

Competing companies

P/E Multiple Summit Therapeutics Inc|Price to Earnings Ratio MRNA (Moderna Corp)|PCVX (Vaxcyte Corp) - Company Value to Net Income|P/E Multiple TARS (tarsusrx.com)|Business Payback Period serestherapeutics.com (MCRB)|SPRO - Price to Earnings Ratio|SCYX (scynexis.com) - Price to Earnings Multiple|ANTX: P/E Multiple|Market Cap to Net Income PYPD (PolyPid Ltd)|LSB (ysbiopharm.com) - P/E Multiple|Market Cap to Earnings Iterum Therapeutics plc ITRM|P/E Multiple PHGE|Price to Earnings Ratio BioPharma Bio SNGX|60 Degrees Pharmaceuticals, Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio OGEN (Oragenics)|opgen.com - P/E Multiple